Download Type here

p
ANALYST UPDATE
October 2, 2002
PLIVA's subsidiary launches new branded generic on the US market
PLIVA d.d. ("PLIVA") is pleased to announce that its recently acquired company in the US has
launched a new innovative branded generic with improved properties for the treatment of
bronchospasm. Odyssey Pharmaceuticals ("Odyssey"), a subsidiary of Sidmak Laboratories,
obtained registration approval from the FDA for VoSpire ER (albuterol sulfate) 4-mg and 8-mg
extended release tablets, which will be introduced on the market this week. VoSpire ER is indicated
for the relief of bronchospasm in adults and in children 6 years of age and older who have reversible
obstructive airway disease.
VoSpire ER's advantage over other therapeutically equivalent drugs is that it maintains its product
stability at room temperature, without the need for constant refrigeration. This makes it easier for
patients to carry the drug with them anywhere they go and facilitates easier storage for warehouses
as well as pharmacies. It is also an excellent alternative for patients who have difficulty using a
metered-dose inhaler or who prefer an inconspicuous, easy-to-take tablet.
According to IMS data for 2001, sales of therapeutically equivalent products to VoSpire ER
reached US$ 56.8 m in the USA.
For additional information, please contact:
Erika Kašpar
Investor Relations
Director
Tel: 385 1 6120 755
Fax: 385 1 6114 413
E-mail: [email protected]
Tanja Rukavina
Investor Relations
Financial Analyst
Tel: 385 1 6160 336
Fax: 385 1 6114 413
E-mail: [email protected]
Since 1921